Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion

Journal of Virology

Volumn 90, Issue 19, 2016, Pages 8924-8933

  Coleman, Christopher M ^a   Sisk, Jeanne M ^a   Mingo, Rebecca M ^b   Nelson, Elizabeth A ^b   White, Judith M ^b   Frieman, Matthew B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON TYROSINE PROTEIN KINASE 1; ABELSON TYROSINE PROTEIN KINASE 2; CCF2 PROTEIN; IMATINIB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; ARG TYROSINE KINASE; PROTEIN KINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONAVIRUS INFECTION; DRUG DETERMINATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; ID50; IN VITRO STUDY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA SYNTHESIS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; IMATINIB MESYLATE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SARS VIRUS; VIRUS INTERNALIZATION;

EID: 84990252098     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01429-16     Document Type: Article

References (38)

1. Fehr AR, Perlman S. 2015. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1-23. http://dx.doi.org/10.1007/978-1-4939-2438-7_1
2. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 102:11876-11881. http://dx.doi.org/10.1073/pnas.0505577102
3. Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Haagmans BL, Pelkmans L, Rottier PJ, Bosch BJ, de Haan CA. 2014. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog 10:e1004502. http://dx.doi.org/10.1371/journal.ppat.1004502
4. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, Stanton LW. 2004. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10:581-586. http://dx.doi.org/10.3201/eid1004.030458
5. Sirois S, Wei DQ, Du Q, Chou KC. 2004. Virtual screening for SARSCoV protease based on KZ7088 pharmacophore points. J Chem Infect Comput Sci 44:1111-1122. http://dx.doi.org/10.1021/ci034270n
6. Chou KC, Wei DQ, Zhong WZ. 2003. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 308:148-151. http://dx.doi.org/10.1016/S0006-291X(03)01342-1
7. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763-1767. http://dx.doi.org/10.1126/science.1085658
8. Hertzig T, Scandella E, Schelle B, Ziebuhr J, Siddell SG, Ludewig B, Thiel V. 2004. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 85:1717-1725. http://dx.doi.org/10.1099/vir.0.80044-0
9. Adedeji AO, Singh K, Calcaterra NE, DeDiego ML, Enjuanes L, Weiss S, Sarafianos SG. 2012. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother 56:4718-4728. http://dx.doi.org/10.1128/AAC.00957-12
10. Huang JD, Zheng BJ, Sun HZ. 2008. Helicases as antiviral drug targets. Hong Kong Med J 14(Suppl 4):S36-S38
11. Adedeji AO, Singh K, Sarafianos SG. 2012. Structural and biochemical basis for the difference in the helicase activity of two different constructs of SARS-CoV helicase. Cell Mol Biol (Noisy-le-grand) 58:114-121
12. Wong SS, Yuen KY. 2008. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 62:437-441. http://dx.doi.org/10.1093/jac/dkn243
13. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear CM, Glass PJ, Hensley LE, Frieman MB. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory coronavirus infection. Antimicrob Agents Chemother 58: 4885-4893. http://dx.doi.org/10.1128/AAC.03036-14
14. Garcia M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, Nabel GJ. 2012. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med 4:123ra124
15. Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A. 2014. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3:e84. http://dx.doi.org/10.1038/emi.2014.88
16. Coyne CB, Bergelson JM. 2006. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124: 119-131. http://dx.doi.org/10.1016/j.cell.2005.10.035
17. Newsome TP, Weisswange I, Frischknecht F, Way M. 2006. Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus. Cell Microbiol 8:233-241. http://dx.doi.org/10.1111/j.1462-5822.2005.00613.x
18. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3:e5. http://dx.doi.org/10.1371/journal.ppat.0030005
19. Frieman M, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, WoodruffB, Scorpio D, Subbarao K, Baric RS. 2012. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol 86:884-897. http://dx.doi.org/10.1128/JVI.05957-11
20. Coleman CM, Frieman MB. 2015. Growth and quantification of MERSCoV infection. Curr Protoc Microbiol 37:2-15. http://dx.doi.org/10.1002/9780471729259.mc15e02s37
21. Taylor JK, Coleman CM, Postel S, Sisk JM, Bernbaum JG, Venkatarajan T, Sundberg EJ, Frieman MB. 2015. Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference. J Virol 89:11820-11833. http://dx.doi.org/10.1128/JVI.02274-15
22. Mingo RM, Simmons JA, Shoemaker CJ, Nelson EA, Schornberg KL, D'Souza RS, Casanova JE, White JM. 2015. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol 89:2931-2943. http://dx.doi.org/10.1128/JVI.03398-14
23. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. 2013. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13:559-571. http://dx.doi.org/10.1038/nrc3563
24. Colicelli J. 2010. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 3:re6. http://dx.doi.org/10.1126/scisignal.3139re6
25. Bradley WD, Koleske AJ. 2009. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci 122:3441-3454. http://dx.doi.org/10.1242/jcs.039859
26. Wang J, Pendergast AM. 2015. The emerging role of ABL kinases in solid tumors. Trends Cancer 1:110-123. http://dx.doi.org/10.1016/j.trecan.2015.07.004
27. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. 2006. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790-5797. http://dx.doi.org/10.1158/0008-5472.CAN-05-4187
28. Seabra MC, Coudrier E. 2004. Rab GTPases and myosin motors in organelle motility. Traffic 5:393-399. http://dx.doi.org/10.1111/j.1398-9219.2004.00190.x
29. Sandilands E, Frame MC. 2008. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol 18:322-329. http://dx.doi.org/10.1016/j.tcb.2008.05.004
30. Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pohlmann S. 2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 85:4122-4134. http://dx.doi.org/10.1128/JVI.02232-10
31. Bertram S, Glowacka I, Muller MA, Lavender H, Gnirss K, Nehlmeier I, Niemeyer D, He Y, Simmons G, Drosten C, Soilleux EJ, Jahn O, Steffen I, Pohlmann S. 2011. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 85:13363-13372. http://dx.doi.org/10.1128/JVI.05300-11
32. Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, Glowacka I, Welsch K, Winkler M, Schneider H, Hofmann-Winkler H, Thiel V, Pohlmann S. 2013. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol 87:6150-6160. http://dx.doi.org/10.1128/JVI.03372-12
33. Leow MK. 2013. Correlating cell line studies with tissue distribution of DPP4/TMPRSS2 and human biological samples may better define the viral tropism of MERS-CoV. J Infect Dis 208:1350-1351. http://dx.doi.org/10.1093/infdis/jit330
34. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H, Pohlmann S. 2013. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87:5502-5511. http://dx.doi.org/10.1128/JVI.00128-13
35. Simmons G, Zmora P, Gierer S, Heurich A, Pohlmann S. 2013. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 100:605-614. http://dx.doi.org/10.1016/j.antiviral.2013.09.028
36. Shirato K, Kawase M, Matsuyama S. 2013. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 87:12552-12561. http://dx.doi.org/10.1128/JVI.01890-13
37. Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. 2015. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29:1123-1132. http://dx.doi.org/10.1038/leu.2015.36
38. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. 2005. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 11:6987-6993. http://dx.doi.org/10.1158/1078-0432.CCR-05-0622